A growing number of neurodegenerative diseases are caused by expansion of CAG trinucleotide repeats coding for polyglutamine. T h e presence of intranuclear inclusions in the affected neuronal cells has suggested a mechanism for pathogenesis based on protein misfolding and aggregation. Detailed understanding of these phenomena is therefore crucial in order to rationalize different phases of the diseases. In the past decade, a few studies have focused on the structural properties of polyglutamine and on the molecular bases of the aggregation process. Most of these studies have been performed on polyglutamine peptides and protein models. Only one report is currently available on the characterization of a full-length polyglutamine protein. The structural hypotheses resulting from these studies are reviewed here.
Introduction
Expansion of unstable CAG trinucleotide repeats coding for polyglutamine is the cause of several inherited neurodegenerative diseases, that include Huntington's disease, spinobulbar muscular atrophy, dentatorubral-pallidoluysian atrophy and spinocerebellar ataxias (SCAs) 1, 2, 3, 6, 7 and 17 [ 11. T h e polyglutamine regions are the only feature shared by the related proteins [2] . Although the function of most of these proteins remains unknown, they seem to be involved in different cellular processes and, when expanded, they affect different subsets of neuronal cells [l] . T h e pathogenic threshold is x 3 5 4 0 glutamines for all disorders, except for SCA6 [3] . A common characteristic of polyglutamine disorders is the formation of intranuclear protein aggregates that contain the expanded glutamine repeats and show a granular or fibrillar morphology [4] . T h e role of these nuclear inclusions in pathogenesis is controversial. Experimental evidence indicates that they are toxic for neuronal cells and thus a direct cause of Key words: aggregation, neurodegenerative disease, polyglutamine, structure.
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In support of a toxic gain of function mechanism, Perutz and Windle [6] have recently shown that the kinetics of neuronal death and the dependence of the age of onset on the repeat length are fully consistent with a direct involvement of polyglutamine aggregation in the pathology. However, other studies suggest that the nuclear inclusions are not required for disease initiation and could be a consequence of the cell's attempts to eliminate the mutated protein [S] . Nonetheless, understanding the process of protein aggregation mediated by polyglutamine expansions could provide helpful insights into the mechanism of pathogenesis and/ or the subsequent stages of these diseases.
Structural hypotheses
In studies of N-terminal huntingtin peptides, Scherzinger et al. showed that polyglutamine sequences can form insoluble aggregates in vitro in the absence of other cellular partners, and that the aggregation process depends on repeat length as well as on time and protein concentration [7, 8] . These results suggested that aggregation could be triggered by a conformational transition occurring in expanded polyglutamine regions. T h e hypothesis of protein misfolding and subsequent aggregation is supported by the observation that the nuclear inclusions contain ubiquitin, chaperones and components of the proteosomal apparatus [3] . Furthermore, antibodies have been obtained that selectively recognize expanded polyglutamine sequences [9] .
T h e first structural hypothesis on the role of polyglutamine regions in aggregation was formulated by Max Perutz. In a seminal paper published in 1993, he suggested that polyglutamines could form 'polar zippers' made of anti-parallel @-strands held together by hydrogen bonds between both main-chain and side-chain amides [lo] . Other molecular modelling studies have proposed a random-coil-to-@-hairpin transition for expanded glutamine repeats [l 11, or an ensemble of four possible motifs for polyglutamine, including parallel and anti-parallel @-sheets, a-helix and n-helix [12].
Perutz's polar zipper hypothesis inspired most of the subsequent structural studies and was tested using several different model systems. However, the experimental work had to confront a limitation, which is probably the actual cause of protein aggregation : polyglutamine is insoluble in water and readily aggregate to form viscous gels, as shown in an early study on synthetic polymers by Krull and Wall [13] . The authors showed that solid polyglutamine is characterized by the formation of interamide hydrogen bonds that may result in strongly associated sheets in a parallel p-structure. In order to overcome the solubility problem, polyglutamine peptides were inserted into different peptide or protein sequences.
Peptide models
In 1994, Perutz et al. studied a synthetic peptide containing 15 glutamines flanked by charged residues (Asp,-Gln,,-Lys,) [14] . CD, electron and X-ray diffraction data showed that this peptide forms hydrogen-bonded hairpins and aggregates into pleated p-sheets. In a study of a peptide comprising 22 glutamines dissolved in aqueous solution by adding 20j0 DMSO, Sharma et al. reached similar conclusions [15] . C D and solidphase Fourier-transform infrared spectroscopy indicated that the polyglutamine peptide forms intramolecular p-hairpins at low concentrations, and that it aggregates through formation of large intermolecular /?-sheet structures at higher concentrations. T h e properties of this peptide were compared with those of polyglutamine with inserted histidines, to mimic the situation of ataxin-1, the protein responsible for the SCAl disease. In normal individuals, the polyglutamine region in ataxin-1 is interrupted by histidines, while it is uninterrupted and expanded in SCAl patients [16] . T h e results showed that the inclusion of histidines made the peptides soluble in water and reduced their propensity to aggregate, although they retained a B-sheet structure [15] .
In contrast, in a CD study of synthetic polyglutamine peptides flanked by sequences rich in alanine and lysine, Altschuler et al. showed that polyglutamine stretches of 9 or 17 residues in aqueous solution are monomeric and adopt a random-coil conformation [17] . These results were confirmed by the work carried out by Chen et al. on glutamine sequences flanked by pairs of lysine residues, solubilized using a mixture of trifluoroacetic acid and hexafluoroisopropanol, and studied in water at pH 3 [18, 19] . The experimental results indicated that, under the conditions studied, all polyglutamine peptides, irrespective of their length, are in a random-coil conformation. However, sequences with more than 37 glutamine residues showed a much greater tendency to form amyloid-like aggregates, with kinetics characteristic of a nucleation-dependent aggregation process.
T h e apparent contradictions of the studies reported above may be reconciled into a unifying picture by considering that the results are dominated by the strong tendency of polyglutamine to aggregate in water. T h e experiments were performed with different sequences and in various solvent conditions, and this may result in different extents of solubilization. It is thus possible that the random-coil conformation is only observed when the solvent composition and the flanking stretches induce full solubility of the polyglutamine stretches, and that p-hairpin or p-sheet structures are observed when polyglutamine is partially aggregated. Nonetheless, the consensus view of the work on polyglutamine peptides seems to be that polyglutamine aggregates contain /?-structures.
Although the field has been dominated by Perutz's hypothesis, an alternative conformation for polyglutamine expansions has been proposed. Based on molecular modelling and experimental studies, Monoi et al. suggested that expanded polyglutamine chains could adopt a stable p-helical structure and form toxic, membranedepolarizing cation channels, causing neuronal death [20, 21] . T h e formation of long-lived ion channels by polyglutamine stetches in vitro was also reported by Hirakura et al. [22] . A similar mechanism for pathogenesis was suggested for other neurodegenerative disorders, such as Alzheimer's disease, prion disease, diabetes mellitus and dialysis-associated amyloidosis. In fact, several classes of amyloid peptides have been shown to form ion channels in lipid membranes ([23] and references therein). The possibility of a gain-offunction mechanism along these lines is therefore worthy of consideration. In polyglutamine diseases, however, the formation of membrane channels in neuronal cells has never been directly observed and any correlation between the presence of nuclear protein aggregates and channel formation is yet to be rationalized.
Protein models
More elaborate model systems have been developed in attempts to reproduce more closely the Amyloidogenic Proteins Involved in Neurodegeneration and Therapeutic Implications protein context. Since Ordway et al. demonstrated that neurotoxicity of polyglutamine stretches may be independent of the specific protein in which they are inserted [24] , different protein hosts have been used. Perutz and co-workers inserted a GlyGln,,-Gly peptide into the inhibitory loop of chymotrypsin inhibitor 2 (CI2), a small protein of known structure [25] . X-ray and NMR solution studies showed that the polyglutamine region in the mutant C12 is in a random-coil conformation [26, 27] . Studies of the stability and folding rates of the same mutant protein also showed that the insertion of the polyglutamine tract had little effect on the folding properties of C12 1281.
In another model system, polyglutamine stretches of different length were inserted into sperm whale myoglobin and studied using several spectroscopic methods [29] . T h e results showed that the expanded polyglutamine regions form anti-parallel P-sheet structures. A model was suggested in which short polyglutamine regions would form intramolecular P-sheets buried in the core of the protein. In contrast, repeats in the pathological length range would form P-sheet structures that protrude into solution, destabilizing the protein structure and inducing aggregation through intermolecular interactions.
Recently, we have developed a model system consisting of 22 and 41 glutamines fused to glutathione S-transferase (GST), a wellcharacterized protein of known structure and high stability 1301. A similar system was used in previous studies to investigate the influence of repeat length on expression patterns in Escherichia coli [31] . GST fusion proteins were also used to study the aggregation properties of huntingtin exon 1 [7, 8, 32, 33] . However, in this case GST was mostly used as a carrier and the polyglutamine sequences were studied only after proteolytic cleavage from G S T . In our work, the uncleaved constructs allowed the direct observation of the solution structure of polyglutamine sequences both below and above the disease threshold in a protein context. Using different biophysical techniques, including NMR and optical spectroscopies, we showed that unaggregated polyglutamine stretches are exposed to solvent and are in a random-coil conformation. In addition, the results indicated that the solubility and the stability of the polyglutamine regions are strongly affected by those of GST. However, under destabilizing conditions the aggregation behaviour of polyglutamine is determined by the repeat length.
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Thus, the studies on polyglutamine-fusion proteins clearly show that, while these constructs can mimic the protein environment and hence provide apparently closer models for polyglutaminecontaining proteins, the specific choice of the carrier protein may influence the properties of the glutamine repeats under investigation. A more direct study of the proteins responsible for polyglutamine diseases is therefore desirable for the future. However, the characterization of fulllength polyglutamine proteins has been complicated by their large size and by difficulties in their expression. T h e only study currently available on intact polyglutamine proteins is that on ataxin-3, the protein linked to SCA3 disease. T h e structural properties and the aggregation behaviour of ataxin-3 were investigated by Bevivino and Loll 1341, who showed that the glutamine expansions destabilize the native protein conformation and induce aggregation and formation of insoluble fibres. Analysis of the secondary structure of the fibres by infrared spectroscopy indicated a high content of parallel /?-sheet structure. We are currently applying the approach used for our previous work on GST-polyglutamine fusion proteins [30] to members of the polyglutamine protein family. T h e aim of this work is not only to characterize the properties of polyglutamine stretches in the pathological length, but also to investigate the structural features of the native, non-expanded proteins.
Conclusions
Although the role of nuclear inclusions and fibres in the pathogenesis of polyglutamine diseases is not yet clear, knowledge of the mechanism underlying aggregation of polyglutamine regions remains a crucial step in order to rationalize the molecular bases of different phases of the disorders. Furthermore, a mechanism involving protein misfolding and aggregation has been postulated for several other neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and prion disease [35, 36] . A unifying picture that emerges from the studies reviewed here can be summarized as follows. Most of the models proposed so far point towards aggregation being the result of a conformational transition to P-sheet structures, consistent with the fibril morphology observed in Alzheimer's disease [37] . Increasing evidence shows that, when polyglutamine sequences are solubilized by highly soluble carriers, they have random-coil conformations. However, when expanded, they destabilize the native protein conformation and promote aggregation through the formation of intermolecular /I-sheets.
T h e specific events that trigger the structural transition are yet to be determined. T h e increase in the number of glutamines in the mutated proteins is most likely in itself a cause of reduced solubility and precipitation. As shown by studies that suggest a nucleation mechanism for aggregation, the frequency of nucleation and aggregate growth rate, observed both in cellular cultures and in vitro, increase with number of glutamines and protein concentration ([6] and references therein ; [ 181). However, other mechanisms could also be responsible for aggregate formation. Proteolytic cleavage of the polyglutamine region from the intact protein, known to be important for aggregate formation in Huntington's disease [38] , may play a more general role in the initiation of other, if not all, polyglutamine disorders. If this were the case, it would clearly influence the choice of further model systems. A detailed understanding of the steps that precede and promote aggregation could therefore provide the basis for the development of new therapeutic strategies.
